Last reviewed · How we verify

Ambroxol Hydrochloride (420mg)

University College, London · Phase 3 active Small molecule

Ambroxol Hydrochloride (420mg) is a Mucolytic agent Small molecule drug developed by University College, London. It is currently in Phase 3 development for Acute and chronic bronchitis, Bronchiectasis, Asthma with mucus hypersecretion. Also known as: Ambroxol.

Ambroxol is a mucolytic agent that breaks down and reduces the viscosity of respiratory mucus, facilitating clearance from the airways.

Ambroxol is a mucolytic agent that breaks down and reduces the viscosity of respiratory mucus, facilitating clearance from the airways. Used for Acute and chronic bronchitis, Bronchiectasis, Asthma with mucus hypersecretion.

At a glance

Generic nameAmbroxol Hydrochloride (420mg)
Also known asAmbroxol
SponsorUniversity College, London
Drug classMucolytic agent
ModalitySmall molecule
Therapeutic areaRespiratory
PhasePhase 3

Mechanism of action

Ambroxol works by stimulating serous cells in the respiratory tract to increase mucus secretion while simultaneously reducing mucopolysaccharide chains, thereby decreasing mucus viscosity and elasticity. This dual action improves mucociliary clearance and makes expectoration easier. It may also have anti-inflammatory and antioxidant properties that support respiratory health.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ambroxol Hydrochloride (420mg)

What is Ambroxol Hydrochloride (420mg)?

Ambroxol Hydrochloride (420mg) is a Mucolytic agent drug developed by University College, London, indicated for Acute and chronic bronchitis, Bronchiectasis, Asthma with mucus hypersecretion.

How does Ambroxol Hydrochloride (420mg) work?

Ambroxol is a mucolytic agent that breaks down and reduces the viscosity of respiratory mucus, facilitating clearance from the airways.

What is Ambroxol Hydrochloride (420mg) used for?

Ambroxol Hydrochloride (420mg) is indicated for Acute and chronic bronchitis, Bronchiectasis, Asthma with mucus hypersecretion, Cystic fibrosis (investigational).

Who makes Ambroxol Hydrochloride (420mg)?

Ambroxol Hydrochloride (420mg) is developed by University College, London (see full University College, London pipeline at /company/university-college-london).

Is Ambroxol Hydrochloride (420mg) also known as anything else?

Ambroxol Hydrochloride (420mg) is also known as Ambroxol.

What drug class is Ambroxol Hydrochloride (420mg) in?

Ambroxol Hydrochloride (420mg) belongs to the Mucolytic agent class. See all Mucolytic agent drugs at /class/mucolytic-agent.

What development phase is Ambroxol Hydrochloride (420mg) in?

Ambroxol Hydrochloride (420mg) is in Phase 3.

What are the side effects of Ambroxol Hydrochloride (420mg)?

Common side effects of Ambroxol Hydrochloride (420mg) include Gastrointestinal disturbances (nausea, diarrhea), Headache, Rash or allergic reactions.

Related